DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to... DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.
- Mechanism
- Curator reviewed
DG051 is an inhibitor of leukotriene A4 hydrolase (LTA4H)which has been shown to link to risk of heart attack, and is directly involved in the synthesis of LTB4. By inhibiting LTA4H, DG051 decreases risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.
- Primary indication
- Investigated for use/treatment in myocardial infarction.Curator reviewed
- Code names
- DG051
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with DG051, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account